ENZC holders were so happy to see IPF Immune being available for the U.S. Obviously any stakeholder expects only an increase in revenue from the newly launched product.
Enzolytics has spent enormous resources on developing the IPF Immune by convincing the public that the new innovation may end most immune-related diseases.
Along with NASDAQ and NYSE, OTC stocks are declining. Maybe today ENZC is plunging due to massive stock selling that is backed by panicking individual buyers. Declining 2% isn’t a serious loss when big biotech stocks dip at least 5%.
From the upcoming second-quarter financial report ENZC may show increased revenue from IPF Immune sales.